← Russell 3000 cross-section

LXRX LEXICON PHARMACEUTICALS, INC.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$1.0bn
Revenue TTM
$42m
Net income TTM
$-61m
Free cash flow
Composite score
Sector rank
#1994

Valuation

P / E
EV / EBITDA
EV / sales
21.6
FCF yield
Earnings yield vs 10-yr
-10.64pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-147.4%
EBITDA margin
-130.3%
ROE
-35.0%
ROIC
-154.2%
Revenue growth
24.1%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Exton was director of business development with Invida Pty Ltd and spent seven years with Eli Lilly Australia, where he held a variety of research, business development and sales positions.LEXICON PHARMACEUTICALS, INC., 10-K, period ended 2025-12-31, filed 2026-03-05

Read the full passage →